[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651694":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":60,"collaborators":62,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":26,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":26,"overallStatus":83,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Khyber Girls Medical College","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group","EXPERIMENTAL","This will receive medicine citicoline with standard care",[13],"Drug: Citicoline",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Only receive standard care",[19],"Other: Standard medical treatment",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Citicoline","This group will receive drug and standard care",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Standard medical treatment","This group will receive only standard care",[15],[32],{"name":33,"affiliation":34,"role":35},"Romisa Rehman","Hyatabad Medical Complex","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Romisa Rehman, FCPS, MRCPCH","CONTACT","00923219059305","measa_awan@hotmail.com",[43],{"facility":44,"status":26,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Hayatabad Medical Complex","Peshawar","KPK","25000","Pakistan","PK",{"type":51,"coordinates":52},"Point",[53,54],71.57849,34.008,{"lat":54,"lon":53},[57,58],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},{"name":59,"role":35,"phone":26,"phoneExt":26,"email":26},"Romisa Rehman, MBBS, FCPS, MRCPCH",{"type":61,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[63],{"name":44,"class":64},"OTHER_GOV","100651694","effect-of-citicoline-on-neurological-severity-score-and-cerebral-doppler-resistive-index-in-neonatal-hypoxic-ischemic-encephalopathy-a-randomized-control-trial-100651694",false,"NCT07763145","Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy: A Randomized Control Trial","Inclusion Criteria:\n\n* All inborn neonates diagnosed with APGAR score (Table 2) less then 8\u002F10 at 5 min of life presenting to the emergency room within the first day of life.\n* Outborn babies admitted in the last 24 hours with history or clinical features of perinatal asphyxia.\n\nEXCLUSION CRITERIA :\n\n* Neonates who have received therapeutic hypothermia\n* Neonates with congenital, developmental or chromosomal malformations\n* Significant antenatal risk factors leading to early-onset sepsis\\\\DIC or CNS depression unrelated to asphyxia\n* Preterm neonates \\\u003C35 weeks\n* No consent could be obtained","ALL","0 Hours","24 Hours",{"count":75,"type":76},86,"ESTIMATED","INTERVENTIONAL",[79],"NA","To determine the efficacy of citicoline in improving cerebral blood flow parameters and neurological status among neonates with hypoxic-ischemic encephalopathy using Doppler resistive index and Sarnat-Sarnat score after 72 hours of therapy.",[82],"Hypoxic Ischaemic Encephalopathy (HIE)","NOT_YET_RECRUITING","2026-08-08",{"date":86,"type":87},"2026-08-13","ACTUAL",{"date":89,"type":76},"2026-09-01",{"date":91,"type":76},"2026-12-30",{"name":5,"class":6},1]